Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)

Autor: Powles, Thomas, Kockx, Mark, Rodriguez-Vida, Alejo, Duran, Ignacio, Crabb, Simon J., van der Heijden, Michiel S., Szabados, Bernadett, Pous, Albert Font, Gravis, Gwenaelle, Herranz, Urbano Anido, Protheroe, Andrew, Ravaud, Alain, Maillet, Denis, Mendez, Maria Jose, Suarez, Cristina, Linch, Mark, Prendergast, Aaron, van Dam, Pieter-Jan, Stanoeva, Diana, Daelemans, Sofie, Mariathasan, Sanjeev, Tea, Joy S., Mousa, Kelly, Banchereau, Romain, Castellano, Daniel

Publikováno v: Nature medicine, 26(6). Nature Publishing Group

In the version of this article initially published, the labels in the key to Fig. 1f (red bars, Down in responders; blue bars, Up in responders) were incorrect. The correct labels are as follows: red bars, Up in responders; blue bars, Down in respond

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::96c9bbab2454f745413996e6cd7664da
https://pure.amc.nl/en/publications/publisher-correction-clinical-efficacy-and-biomarker-analysis-of-neoadjuvant-atezolizumab-in-operable-urothelial-carcinoma-in-the-abacus-trial-nature-medicine-2019-25-11-17061714-101038s4159101906287(cf69f704-542f-48b2-b962-85a3d2b989ae).html

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

Autor: Powles, Thomas, Kockx, Mark, Rodriguez-Vida, Alejo, Duran, Ignacio, Crabb, Simon J., Van Der Heijden, Michiel S., Szabados, Bernadett, Pous, Albert Font, Gravis, Gwenaelle, Herranz, Urbano Anido, Protheroe, Andrew, Ravaud, Alain, Maillet, Denis, Mendez, Maria Jose, Suarez, Cristina, Linch, Mark, Prendergast, Aaron, van Dam, Pieter-Jan, Stanoeva, Diana, Daelemans, Sofie, Mariathasan, Sanjeev, Tea, Joy S., Mousa, Kelly, Banchereau, Romain, Castellano, Daniel

Publikováno v: Nature Medicine; 20230101, Issue: Preprints p1-1, 1p

Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.

Autor: Powles T; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK. t.powles@qmul.ac.uk., Kockx M; HistogeneX N.V., Wilrijk, Belgium., Rodriguez-Vida A; Department of Medical Oncology, Hospital del Mar, Barcelona, Spain., Duran I; Instituto de Biomedicina de Sevilla, IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla, Seville, Spain., Crabb SJ; Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK., Van Der Heijden MS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Szabados B; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK., Pous AF; Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO)-IGTP, Hospital Universitari Germans Trias i Pujol, Badalona, Spain., Gravis G; Institut Paoli-Calmettes, Marseille, France., Herranz UA; Department of Medical Oncology, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain., Protheroe A; Department of Medical Oncology, Churchill Hospital, Oxford, UK., Ravaud A; Department of Medical Oncology, Hopital Saint-Andre, University of Bordeaux-CHU Bordeaux, Bordeaux, France., Maillet D; Department of Medical Oncology, Hospital Lyon Sud, Lyon, France., Mendez MJ; Department of Medical Oncology, Reina Sofia University Hospital, Cordoba, Spain., Suarez C; Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain., Linch M; Department of Medical Oncology, University College London Hospital, London, UK., Prendergast A; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK., van Dam PJ; HistogeneX N.V., Wilrijk, Belgium., Stanoeva D; HistogeneX N.V., Wilrijk, Belgium., Daelemans S; HistogeneX N.V., Wilrijk, Belgium.; Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium., Mariathasan S; Genentech, San Francisco, CA, USA., Tea JS; Genentech, San Francisco, CA, USA., Mousa K; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK., Banchereau R; Genentech, San Francisco, CA, USA., Castellano D; Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain.

Publikováno v: Nature medicine [Nat Med] 2020 Jun; Vol. 26 (6), pp. 983.